Product Code: 25-014KA
The in vitro diagnostics (IVD) sector stands as a cornerstone of modern healthcare, empowering clinicians with the tools to detect diseases, monitor health conditions, and guide precise treatment decisions.
SAMPLE VIEW
As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.
"In Vitro Diagnostics Business Outlook" is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:
- Market Data and Forecasts: Detailed growth rates, market size, and market share to identify new opportunities.
- Comprehensive Market View: Coverage of test categories and company profiles.
- M&A Activities: Updates on mergers, acquisitions, partnerships, and collaborations.
- Industry & Region Watch: Tailored strategies based on regional and industry-specific trends.
- News Analysis: In-depth reporting on significant news and events, including exclusive information not readily available elsewhere.
TABLE OF CONTENTS
MARKET ANALYSIS: CARDIAC BIOMARKER TESTING
- OVERVIEW OF CARDIAC BIOMARKERS
MARKET OUTLOOK
- Figure: Cardiac Marker Testing Market by End User, 2024-2029 ($ million) (Lab-based, POC-based)
- Table: Cardiac Marker Diagnostic Sales by End User, 2024-2029 ($ million) (Lab-based, POC-based)
- Figure: Cardiac Marker Testing Market by End User and Total Value Over Time, 2019-2029 ($ million) (Lab-based, PoC-based)
- Figure: Cardiac Marker Testing Market, by Marker, 2024 (% Share) (Troponin, BNP, CK-MB, Myoglobin, Other)
- REGIONAL MARKET
- Table: Cardiac Marker Test Sales Distribution by Global Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
- COMPANY BRIEFS
- Abbott Diagnostics
- Beckman Coulter
- Siemens
- VENDOR MARKET SHARE
- Figure: Market Share of Leading Vendors in the Cardiac Marker Segment, by Company, 2024 (%) (Abbott, Danaher, QuidelOrtho, Roche, Siemens, Others)
EXECUTIVE NEWS BRIEFING
- BRIEFS
- Senseera Closes $7.1 Million in Funding Round
- Geneoscopy Closes Series C Funding
- Oxford Cancer Analytics Raises $11 Million in Series A Funding
- MiRXES Nabs $40 Million in Financing
- Tethis Nabs Euro-15 Million Funding
FINANCIAL HIGHLIGHTS: BECTON DICKINSON, NATERA
- BECTON DICKINSON REPORTS 4% REVENUE GROWTH IN FISCAL 2024
- Table: Becton Dickinson Financial Review, by Business Segment, FY 2022-FY 2024 ($ million) (BD Medical, BD Life Sciences, BD Interventional)
- Figure: Becton Dickinson Business Division Performance, by Business Segment, FY 2022-FY 2024 ($ million) (BD Medical, BD Life Sciences, BD Interventional)
- Figure: BD Life Sciences Division, Segment Mix, FY 2020 vs. FY 2024 (%) (Integrated Diagnostic Solutions, Biosciences)
- Figure: Becton Dickinson U.S./International Revenue Distribution, FY 2022-FY 2024 ($ million)
- Figure: Becton Dickinson Revenue Distribution, by Region, FY 2024 (%) (EMEA, Greater Asia, United States, Other)
- NATERA CONTINUES OVERALL GROWTH TREND WITH PRELIMINARY 2024 RESULTS, EXPECTING A 56% INCREASE OVER 2023
- Figure: Natera Financial Overview by Quarter, Q1 2023-Q4 2024* ($ million)
DIAGNOSTIC MARKET MERGERS, ACQUISITIONS, AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- MERGERS AND ACQUISITIONS
- Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals, Dec. 2023-Jan. 2025
INDUSTRY WATCH
- INDUSTRY WATCH COVID-19/FLU UPDATE
REGION WATCH
- MEXICO
- Figure: Mexico GDP, GDP (PPP), and Health Spending, 1990-2020, estimated 2025 ($ billion)
- Figure: Mexico IVD Market Sales Trends, by Broad IVD Segment, 2016-2024 ($ million) (Clinical Chemistry, Hematology, and Coagulation; Histology; Immunoassays; Microbiology; POC; Others)
BROAD-BASED COMPANY ANNOUNCEMENTS
- ANNOUNCEMENTS
- Roche Secures CE Marking for Mass Spec System
- QIAGEN Receives FDA Clearance for Five-Target Syndromic Panel
- Revvity Secures FDA Clearance for Free Testosterone Test
- Spear Bio Secures FDA Breakthrough Device Designation
- Roche Announces Clearance of First ISH Test B-cell Lymphoma
- Roche Receives Additional FDA Clearance